Company news
Akebia Therapeutics, Inc. (NASDAQ:AKBA) news
Akebia Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters…
Press releases & updates
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
October 6, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
September 14, 2026
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
September 1, 2026
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 5, 2026
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
August 3, 2026
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
July 29, 2026
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
June 10, 2026
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
May 7, 2026
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
May 4, 2026
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
April 30, 2026
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
April 12, 2026
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
April 7, 2026
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
March 31, 2026
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
March 19, 2026
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
March 3, 2026
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
February 25, 2026
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
February 19, 2026
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 3, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
January 11, 2026
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
January 5, 2026
Q32 Bio Sells Complement Inhibitor ADX-097
November 30, 2025
Akebia Announces Establishment of Rare Kidney Disease Pipeline
November 30, 2025
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 23, 2025
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 9, 2025
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
November 5, 2025
Akebia Therapeutics to Present at Upcoming Investor Conferences
November 3, 2025
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
October 29, 2025
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
October 27, 2025
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
October 19, 2025
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
August 20, 2025
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 6, 2025
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 6, 2025
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
August 3, 2025
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
July 30, 2025
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
July 7, 2025
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
June 3, 2025
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
May 27, 2025
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
May 26, 2025
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 12, 2025
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
April 30, 2025
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
April 2, 2025
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
March 24, 2025
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
March 18, 2025
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
March 18, 2025
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
March 12, 2025
Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights
March 5, 2025